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A B S T R A C T
Lipid Phosphate phosphatase 3 (LPP3), encoded by the Plpp3 gene, is an enzyme that dephosphorylates the
bioactive lipid mediator lysophosphatidic acid (LPA). To study the role of LPP3 in the myocardium, we gen-
erated a cardiac specific Plpp3 deficient mouse strain. Although these mice were viable at birth in contrast to
global Plpp3 knockout mice, they showed increased mortality ~ 8 months. LPP3 deficient mice had enlarged
hearts with reduced left ventricular performance as seen by echocardiography. Cardiac specific Plpp3 deficient
mice had longer ventricular effective refractory periods compared to their Plpp3 littermates. We observed that
lack of Lpp3 enhanced cardiomyocyte hypertrophy based on analysis of cell surface area. We found that lack of
Lpp3 signaling was mediated through the activation of Rho and phospho-ERK pathways. There are increased
levels of fetal genes Natriuretic Peptide A and B (Nppa and Nppb) expression indicating myocardial dysfunction.
These mice also demonstrate mitochondrial dysfunction as evidenced by a significant decrease (P< 0.001) in
the basal oxygen consumption rate, mitochondrial ATP production, and spare respiratory capacity as measured
through mitochondrial bioenergetics. Histology and transmission electron microscopy of these hearts showed
disrupted sarcomere organization and intercalated disc, with a prominent disruption of the cristae and vacuole
formation in the mitochondria. Our findings suggest that LPA/LPP3-signaling nexus plays an important role in
normal function of cardiomyocytes.
1. Introduction
The phospholipid phosphatase 3 (PLPP3) gene encodes LPP3, an
integral membrane protein which is Mg2+-independent and N-ethyl-
maleimide insensitive enzyme responsible for the dephosphorylation of
lipid phosphates such as phosphatidic acid (PA) and lysophosphatidic
acid (LPA). It is robustly expressed in the heart [1]. Subcellularly, LPP3
is located in the plasma membrane [2], the endoplasmic reticulum
(ER), Golgi complex and endosomes [3,4]. Global knockout of Plpp3
(formerly Ppap2b) in mice leads to embryonic lethality around em-
bryonic age 10 due to defects in the development of extraembryonic
vasculature [5]. In addition, we have demonstrated that deficiency of
endothelial cell specific LPP3 leads to increased vascular permeability
and defective cardiovascular development resulting in embryonic
lethality [6] and knockout of Plpp3 in both endothelial or smooth
muscle cells shows enhanced inflammation and permeability [6,7].
These findings imply that LPP3 expression is essential for normal pre-
natal cardiovascular development and, in adult mice, LPP3 normally
functions to maintain the vascular integrity and attenuate inflamma-
tion.
Although other functions are likely, LPP3 is a key regulator of the
bioactive lipid LPA and terminates its signaling function through de-
phosphorylation. LPA plays a well-known role in atherosclerotic dis-
ease. A six-fold increase in serum LPA concentration has been observed
following acute myocardial infarction in patients (1.66 mg/L vs
10.43 mg/L, P<0.001) [8]. We have shown that exogenous
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administration of LPA increases heart rate and left ventricular pressure
in vivo [9]. Furthermore, LPA has been shown to induce cardiomyocyte
hypertrophy in cell culture models [10,11]. These findings suggest a
critical role for LPA-mediated signaling in the myocardium. Interrup-
tion of LPA signaling in the myocardium may be an important factor in
protecting the heart against insult and injury. As conventional deletion
of the Plpp3 results in severe embryonic developmental abnormalities
[5], a specific role for the LPP3 enzyme in adult myocardium remains
unknown. Therefore, we used the Cre/loxP system to delete Plpp3
specifically in cardiomyocytes. This strategy resulted in mice which do
not express LPP3 in the heart. Here, we characterize these animals in
order to understand the role of LPP3 in the adult myocardium under
physiological conditions. Our findings indicate that LPP3 serves as an
intrinsic negative regulator of LPA mediated cardiomyocyte hyper-
trophy. These findings suggest that LPP3 is crucial in maintaining the
normal cardiac homeostasis and plays an important role in the pro-
tection of cardiomyocytes in vivo.
2. Material and methods
2.1. Generation of mice with cardiac-specific deletion of Plpp3
The production and initial characterization of mice carrying a
conditional allele of Plpp3 (Plpp3fl) have previously been described
[6,7]. Plpp3fl mice were backcrossed for> 10 generations into the
C57Bl/6 background. These mice were then crossed with C57Bl/6 mice
expressing Cre recombinase under the control of the cardiac-specific
alpha-myosin heavy chain promoter (Myh6-Cre) [12] to obtain con-
genic Plpp3Δ mice.
The mice survived in the expected numbers. Mating of homozygous
Plpp3fl with Plpp3Δ mice yielded 50% Plpp3Δ offspring with less than 2%
mortality at birth. Mice were housed in cages with HEPA-filtered air in
rooms on 12-h light cycles and fed Purina 5058 rodent chow ad libitum.
Systolic blood pressure and heart rate were measured for five con-
secutive days noninvasively in conscious mice using the CODA blood
pressure analysis tail-cuff system (Kent Scientific Corporation,
Torrington, CT) daily after training for one week. All procedures con-
formed to the recommendations of Guide for the Care and Use of
Laboratory Animals (Department of Health, Education, and Welfare
publication number NIH 78-23, 1996), and were approved by the
Institutional Animal Care and Use Committee. Neonatal cardiomyo-
cytes were isolated from the Plpp3fl with Plpp3Δ mice as described
previously [13] (Supplementary video shows the beating neonatal
cardiomyocyte derived from Plpp3fl mice).
Supplementary material related to this article can be found online at
http://dx.doi.org/10.1016/j.redox.2017.09.015.
2.2. Echocardiography
Transthoracic echocardiography was performed on male 8-month-
old, using a 30 MHz probe and the Vevo 3100 Ultrasonograph
(VisualSonics). Mice were lightly anesthetized with 0.8% isoflurane,
maintaining the heart rate at 400–500 beats/min. The hair was re-
moved from the chest using a chemical hair remover (Nair®). The heart
rate and body temperature were maintained and recorded.
Sonographers were blinded as to genotypes being analyzed. Two-di-
mensional directed M-mode echocardiographic images along the para-
sternal short axis were recorded to determine left ventricular (LV) size
and systolic function. M-mode measurements included the LV internal
dimensions in systole and diastole (LVIDs and LVIDd, respectively) as
well as the diastolic thickness LV posterior wall (LVPWd) and the dia-
stolic interventricular septum thickness (IVSd). Percent fraction short-
ening was calculated as [(LVIDd − LVIDs)/LVIDd] × 100 [14].
2.3. ECGs and electrophysiology studies
Surface resting ECGs and electrophysiology studies were performed
on male 12-week-old Plpp3Δ mice and compared with those in an age-
matched group of adult male Plpp3fl control mice. Mice were an-
esthetized with isoflurane (2% for induction and 1.5% for maintenance
of anesthesia; Apollo Tech 3 Vaporizer; NorVap). During EP studies the
mouse body temperature was monitored by an intra-rectal probe and
controlled using mouse pad circuit board equipped with a heating
element (Rodent Surgical Monitor, Indus Instruments, USA). All studies
were performed at 37.0±0.5 °C. We used a Millar 1.1F octapolar EP
catheter (EPR-800; Millar Instruments) inserted via a cut down of the
internal right jugular vein. The catheter was advanced to the right at-
rium and ventricle using electrogram guidance and pacing capture to
verify intracardiac position. A computer-based data acquisition system
(PowerLab 16/30; ADI Instruments) was used to record a 1-lead body
surface ECG and up to 4 intracardiac bipolar electrograms (LabChart
Pro software, version 7; AD Instruments). In brief, the right ventricular
pacing was performed using 2 ms current pulses delivered by an ex-
ternal stimulator (STG-3008 FA; Multi Channel Systems). Ventricular
effective refractory period (VERP) or ventricular tissue refractoriness
and ventricular arrhythmia inducibility were assessed by single extra
stimulation or burst pacing using an automated stimulator. To de-
termine VERP, the single ventricular extra stimulus was placed at a
pacing drive of 100 ms. A drive train of eight paced beats (S1×8) fol-
lowed by delivery of a single extra stimulus (S2) was given until ven-
tricular stimuli failed to result in ventricular depolarization. To induce
ventricular tachycardia, the triple extra stimulation technique was
utilized first. Triple extra stimuli were delivered with S2, S3 or S4 extra
stimuli brought down to a minimum coupling interval of 30 ms (1). If
this maneuver failed to induce ventricular tachycardia (VT), we then
performed burst pacing. Burst pacing started at a 40 ms cycle length,
decreasing by 2 ms every 2 s to a cycle length of 20 ms. Burst pacing
was repeated one minute after the previous burst concluded or the
termination of VT. If the mice were non-inducible for VT, we then re-
peated the above maneuvers after an IP injection of Isoproterenol
(1 ng/g). Ventricular tachycardia was defined as 4 consecutive beats of
ventricular premature depolarizations or more [15].
2.4. RNA isolation and quantitative PCR
Human and mouse Plpp3 lentiviruses were derived as described
previously [7]. Total RNA was extracted from heart tissues and primary
cardiomyocytes using the RNeasy mini kit (Qiagen, Chatsworth, CA)
following manufacturer's instructions. cDNA was prepared with Multi-
scribe reverse transcriptase enzyme (High-Capacity cDNA Archive Kit;
Applied Biosystems, Foster City, CA), and mRNA expression was mea-
sured in a RT-PCR reaction using TaqMan® gene expression assays and
TaqMan® Universal PCR Master Mix No Amp Erase® (Applied Biosys-
tems) on an ABI 7500 Fast Real-Time PCR System (Applied Biosystems).
Threshold cycles (CT) were determined by an in-program algorithm
assigning a fluorescence baseline based on readings prior to exponential
amplification. An embryo RNA standard was used as a positive control.
Fold change in expression was calculated using the 2-ΔΔCT method using
18 S RNA as an endogenous control [7].
2.5. Quantification of intracellular superoxide and LPA by mass
spectrometry
Dihydroethidium (DHE, Invitrogen), which exhibits blue fluores-
cence in the cytosol until oxidized, was used to estimate the levels of
superoxide after LPA treatment. The procedures for DHE were con-
ducted using a FACScan protocol using a flow cytometry. For the
quantitation of LPA molecular species, we used HPLC-tandem mass
spectrometry as previously described [6,7]. Analysis of LPA was carried
out using Waters Acquity UPLC coupled with a XEVO TQ-MS ESI mass
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spectrometer. Sphingosine-1-phosphate (S1P) was used as an internal
standard. S1P and LPA (Avanti Polar Lipid, Inc.) were separated using a
Waters BEH C18 column, 1.7 µm, 2.1 × 50 mm column. The mobile
phase consisted of 60/40 acetonitrile/water with formic acid (0.1%)
and 5 mM ammonium formate (0.1%) as solvent A and 95/5 acetoni-
trile/water with formic acid (0.1%) and 5 mM ammonium formate
(0.1%) as solvent B. For the analysis of S1P and LPA the separation was
achieved using gradient of 0–100% B in the next 4 min, maintained at
100% B for the next 6 min and equilibrated back to the initial condi-
tions in 5 min. The flow rate was 0.3 ml/min with a column tempera-
ture of 40 °C. The sample injection volume was 5 μL. The mass spec-
trometer was operated in full scan mode, scanning from m/z 70–500
with a scan time of 200 ms. The positive electrospray ionization mode
for S1P and negative electrospray ionization mode for LPA were se-
lected. The optimal ion source conditions were determined by S1P and
LPA with a capillary voltage 3.82 V, cone voltage 17 V, desolvation
temperature 450 °C, desolvation gas flow 1000 L/h, source temperature
150 °C, collision energy 10 V and Ion source temperature was 150 °C.
S1P was detected by positive mode [M]+ 365.2 and LPA was detected
by negative mode [M-H]− 421.2 of full scan mode.
2.6. Mitochondrial isolation
Heart mitochondria were isolated as described previously by Mela
and Seitz [16]. Briefly, the hearts were collected, washed in ice-cold
isolation buffer (0.225 M mannitol, 0.075 M sucrose, 1 mM EGTA, pH
7.4), and was homogenized at 500 rpm with a chilled Teflon pestle in a
glass cylinder with 10 strokes. The homogenate was centrifuged at
480×g at 4 °C for 5 min. The pellet was rinsed with 0.5 ml of the iso-
lation buffer with gentle shaking to remove the “fluffy layer” (damaged
mitochondria) on top of the pellet. The wall of the centrifuge tube was
cleaned with cotton swabs to remove lipids. The pellet was washed by
Fig. 1. Experimental design of the generation of
Plpp3Δ mice. A) Strategy for generating cardiac-spe-
cific alpha myosin-heavy chain LPP3 knockout mice.
i) The genomic structure of an 11 kb BamHI fragment
containing exons 3 and 4 of the wildtype Plpp3 locus
(gray boxes) and structure of the targeting construct.
ii) A floxed PGKneo cassette was introduced upstream
of exon 3, and an orphan loxP site and a SalI re-
striction site were introduced downstream of exon 4.
iii) The structure of the targeted allele before
(Plpp3fl) and iv) after complete Cre-mediated re-
combination (Plpp3Δ). Small arrows with numbers
show the position of oligonucleotides used for PCR
genotyping and the size of the amplified products: X,
XmaI; S, SalI; B, BamHI; Xb, XbaI; M, MunI; K, KpnI,
H, HindIII; E, EcoRI. B) PCR screening for the totally
recombined allele, orphan loxP present is 235 bp (fl),
and excision of PGKneo and exons 3–4 is 162 bp (Δ).
C) LPP3 mRNA expression was measured in heart
tissue from Plpp3fl and Plpp3Δ mice and reported re-
lative to values in Plpp3fl heart (mean± SD from n=
3 animals per genotype). D) Western blotting de-
monstrates LPP3 protein expression in Plpp3fl and
Plpp3Δ with β-actin used as a loading control. LPP3
expression was normalized to β-actin staining (n = 3
animals) and presented as mean± SD in arbitrary
units in which the density of Lpp3 in the Plpp3fl
samples was set to 1. E) Lpp3 activity was de-
termined in Lpp3 immunoprecipitates from the heart
(n = 3 animals per genotype). Results are reported
as pmol/min/μg protein (mean±SD; n = 3 mice
per genotype). *P< 0.05 by t-test vs control.
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gentle resuspension in 3 ml isolation buffer using the smooth surface of
a glass rod and centrifuged at 7700×g at 4 °C for 10 min. At every step,
the supernatant was saved to check again for leakage from the mi-
tochondria. The resulting mitochondria were collected for further
analysis. The purity of mitochondria was examined using Lamin B (a
nuclear protein) and IκB-α (a cytoskeletal protein) as indicators by
western blotting. Protein content in the lysate was determined by BCA
protein assay (Pierce, Rockford, IL).
2.7. Mitochondrial bioenergetics
Oxygen consumption was determined using the Seahorse
Fig. 2. Cardiac dysfunction exhibited in Plpp3Δ mice.
A) Kaplan-Meier analysis of survival probabilities for
the Plpp3Δ (n = 36) vs the Plpp3fl (n = 38) animals
(left) and the hearts of the 8-month-old Plpp3Δ mice
are significantly larger than the heart of the Plpp3fl
mice (right). B) Representative hematoxylin and
eosin-stained hearts (LV) from Plpp3Δ as compared to
their Plpp3fl littermates with immersion fixation. C)
Masson's trichrome stained Plpp3Δ hearts (LV) show
increased density of connective tissue collagen ma-
trix deposition. All analyses were carried out with 8-
month-old mice. Scale bars 100 µm. D) Transmission
electron micrograph of the 8-month-old myocardium
(LV) from Plpp3Δ as compared to their Plpp3fl litter-
mates. Plpp3Δ myocardium showed distorted (ID)
intercalated disc with damaged mitochondria (Mi).
Mitochondrial insert showing disorganization of
cristae (C), vacuole formation (V) and amorphous
matrix densities in Plpp3Δ as compared to Plpp3fl. Bar
denotes 500 nm.
M. Chandra et al. Redox Biology 14 (2018) 261–271
264
Extracellular Flux (XF-24) analyzer (Seahorse Bioscience, Chicopee,
MA). The XF-24 measures the concentration of oxygen and free protons
in the medium above a monolayer of cells in real-time. Thus, the rates
of oxygen consumption and proton production can be measured across
several samples at a time. To allow comparison between experiments,
data are presented as oxygen consumption rate (OCR) in pmol/min/µg
Fig. 3. Echocardiographic indices of Plpp3Δ mice. A) Bar graph
shows percentage changes in fractional shortening (%FS) and
ejection fraction (%EF) in Plpp3Δ mice compared to their Plpp3fl
littermates (n = 6) as measured echocardiography. B) Bar
graph show representative hearts with an HW/BW ratio, left
ventricular (LV) mass, diastolic left ventricular internal dia-
meter (LVID; d) and systolic left ventricular internal diameter
(LVID;s). C) Electrophysiology studies show inducible ven-
tricular tachycardia (VT) and ventricular effective refractory
periods (VERP) were significantly elevated in Plpp3Δ mice as
compared to their Plpp3fl littermates (n = 6). D) Real-time RT-
PCR shows fold differences in mRNA of Nppa and Nppb with the
value of Plpp3fl defined as 1 (mean± SD, n = 4 each).
*P< 0.05 by t-test vs control. E) Steady state plasma levels of
total LPA from the circulation of live mice from Plpp3fl control
and Plpp3Δ were measured by LC-MS/MS. Values are expressed
as a fold increase over control and graphed as mean± SD from
n = 5 animals per time point. *P< 0.01 compared to control.
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protein and the extracellular acidification rate (ECAR) in mpH/min/µg
protein. Neonatal cardiomyocytes were seeded at 100,000 cells/well
into gelatin-coated Seahorse Bioscience XF microplates, cultured in the
presence or absence of 2 g/L D-glucose, and then centrifuged to adhere
to the bottom of the wells. OCR was measured four times and plotted as
a function of cells under the basal condition followed by the sequential
addition of oligomycin (1 μg/ml, an inhibitor of mitochondrial ATP-
synthase) was injected into the XF medium to estimate the OCR coupled
to ATP synthesis and represented as ATP-linked. The residual oligo-
mycin/OCR minus the non-mitochondrial OCR (after antimycin A
treatment) can be attributed to proton leak. FCCP (0.5 μM), an un-
coupler, is added to determine the maximal OCR, followed by anti-
mycin (1 μM), an inhibitor of mitochondrial respiration, to determine
non-mitochondrial sources of oxygen consumption. The ATP-linked
OCR was calculated as the difference between the basal OCR and the
OCR measured after the addition of oligomycin. The OCR maximal
capacity was the direct rate measured after the addition of FCCP minus
non-mitochondrial respiration. Spare respiratory capacity is a measure
of the amount of ATP that can be produced under energetic demand and
can be calculated as the difference between the maximum rate of re-
spiration and the basal. The OCR values were normalized to total pro-
tein content in the corresponding wells and expressed as pmol/min/mg
protein.
To calculate ECAR measurements, cells were washed and changed
to assay medium lacking glucose. Basal ECAR were measured four times
and plotted as a function of cells under the basal condition followed by
the sequential addition of glucose (25 mM), oligomycin (1 μg/ml) and
2-deoxyglucose (25 mM), an inhibitor for the hexokinase. The rate of
glycolysis was determined by the difference between the basal ECAR
from the ECAR after the addition of glucose. The glycolytic reserve was
determined by subtracting the ECAR following the addition of oligo-
mycin from the ECAR following the addition of glucose.
2.8. Histology and electron microscopy
The hearts were collected at 8 months of age, fixed in 10% buffered
formalin, and embedded in paraffin. Serial 5-μm heart sections from
each group were stained with hematoxylin and eosin or Masson's tri-
chrome [17]. For electron microscopy, the left ventricles were dissected
from hearts, and fixed in 2% EM-grade glutaraldehyde (Sigma), 2% PFA
in 0.2 M sodium cacodylate (pH 7.4; Sigma) overnight at 4 °C, and post-
fixed in 1% osmium tetroxide (EM Sciences) in 0.2 M sodium cacody-
late (pH 7.4) for 2 h at 4 °C. Tissue was treated with propylene oxide
and resin embedded (EMBED 812 kit, EM Sciences). The osmicated
samples were then dehydrated through a series of graded ethanol so-
lutions and then infiltrated with propylene oxide (EM Sciences). Sub-
sequently, the tissues were infiltrated with Durcupan ANC Fluka Ara-
ldite (Sigma Chemical) and embedded in the same resin. After
polymerization, 80-nm sections were cut using a Reichert Ultracut E
Ultramicrotome (Leica Microsystems, Bannockburn, IL), and the grids
were subsequently stained with uranyl acetate and lead citrate. The
sections were imaged using a Hitachi transmission electron microscope
equipped for digital image acquisition.
2.9. Statistical analysis
Unless otherwise stated, results were expressed as a mean±
standard deviation of the mean. In vitro studies were repeated a
minimum of three times. One-way analysis of variance (ANOVA) fol-
lowed by the Bonferroni post hoc test or the unpaired Student's t-test
was used to identify significant differences between groups. Statistical
analysis was performed using Sigma-STAT software, version 3.5 (Systat
Software Inc., San Jose, CA, USA). A P-value of less than 0.05 was
considered significant.
3. Results
3.1. Generation of mice deficient in LPP3 in cardiac myocytes
Global deletion of Plpp3 results in embryonic lethality due to failure
to develop an extraembryonic vasculature [5]. Furthermore, we have
identified that even a tissue specific deficiency of endothelial-LPP3
exhibits embryonic lethality due to defective cardiovascular develop-
ment [6] and inducible knockouts of LPP3 show enhanced inflamma-
tion and permeability [6,7]. To study the biological function of LPP3 in
the heart, we generated cardiomyocyte specific Plpp3 knockout mice.
For this purpose, we utilized Plpp3fl mice with two loxP sites flanking
exons 3 and 4 of the Plpp3 locus [18]. These mice were crossed with
mice expressing Cre recombinase under the control of the cardiac-
specific alpha-myosin heavy chain promoter (Myh6-Cre) [12] to gen-
erate Myh6-LPP3-deficient mice (Plpp3Δ) (Fig. 1A).
3.2. Analysis of LPP3 expression
Recombination in the Plpp3 locus was confirmed by PCR analysis
(Fig. 1B). To provide biochemical evidence that LPP3 expression is
deficient in the heart, we looked at mRNA expression of LPP3 in
knockout mice heart tissue, which was confirmed to be negligible when
compared to the Plpp3fl mice (Fig. 1C). Immunoblot analysis of heart
tissue was performed to determine LPP3 protein expression. As shown
in Fig. 1D, LPP3 expression was negligible in the heart from Plpp3Δ
mice, when compared to Plpp3fl hearts. When we compare the con-
tribution of LPP3 in cardiomyocytes over the other two isoforms of
phospholipid phosphatases, namely, LPP1 and LPP2, the significantly
reduced phosphatase activity in our Plpp3Δ mice suggest that LPP3 has a
more prominent role in the heart (Fig. 1E).
3.3. Mice lacking LPP3 in the heart have shorter life spans due to decreased
cardiac function
Unlike global Plpp3 knockout mice, Plpp3Δ are viable and fertile. All
mice reached adulthood with no obvious phenotype. However, they
had a decreased life span of ~ 8 months (Fig. 2A). 3-month-old Plpp3Δ
mice showed higher heart rates (642± 21 bpm) compared to Plpp3fl
mice (580±17 bpm; P< 0.01) although the blood pressure was si-
milar in mice from both genotypes (96±9 mmHg; n = 19 in Plpp3fl as
compared to 92±7 mmHg; n = 19 in Plpp3Δ). After 7 months of age,
mutant mice displayed signs of progressive heart failure. They had
enlarged hearts indicating dilated cardiomyopathy (Fig. 2A). Cardiac
tissue samples from 8-month-old mice were stained with hematoxylin
and eosin staining (Fig. 2B) to compare the myocardium. Plpp3Δ hearts
exhibited sarcomere disarray whereas Plpp3fl hearts had no abnormal-
ities. Masson's trichrome stained Plpp3Δ hearts showed increased den-
sity of connective tissue collagen matrix deposition (Fig. 2C). Ultra-
structural studies in Plpp3Δ heart tissue demonstrated myofilament
destruction and absence of glycogen with distinct disruption of the
intercalated discs. Mitochondria showed vacuole formation with pro-
minent disruption of the cristae and rupture of the double membrane
with deposition of an amorphous dense body (Fig. 2D).
Based on the evidence described above, we sought to determine the
performance of the left ventricle in 8-month-old knockout mice using
echocardiography. We observed a significant reduction in the fractional
shortening as well as ejection fraction in mice lacking LPP3 in the heart,
suggesting a decline in the left ventricular function (Fig. 3A). The heart
weight/body weight (HW/BW) ratio and left ventricular (LV) mass
index were also significantly elevated in Plpp3Δ compared to Plpp3fl
control mice (Fig. 3B). Plpp3Δ mice had longer ventricular effective
refractory periods compared to their Plpp3fl littermates (38.25± 1.181
vs 18.67± 0.6667). These mice also had a higher incidence of in-
ducible VT with 1.050± 0.1652 s of VT compared to the controls
(Fig. 3C). Natriuretic peptide A and B (Nppa and Nppb) are secreted by
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Fig. 4. LPP3 negatively regulates LPA signaling responses in neonatal cardiomyocytes. A) expression, immunoblot and activity assay showed the absence of LPP3 in Plpp3Δ cardio-
myocytes (n = 4). B) Increase cell surface area is observed upon stimulation with LPA (1 μM) in Plpp3Δ cardiomyocytes with increased ANF positive cells (n = 4). B) and C) Plpp3Δ
cardiomyocytes showed increased levels of extracellular signal-regulated kinase (ERK) activation upon stimulation with LPA (1 μM) at different time point intervals (n = 3). Where
indicated, cells were infected with lentivirus expressing human (h) LPP3 or a catalytically inactive LPP3 variant. D) Plpp3Δ cardiomyocytes showed increased levels of Rho activation upon
stimulation with LPA (1 μM) (n = 3). E) ERK activation was measured in Plpp3fl and Plpp3Δ cardiomyocytes 5 min after treatment with 2.5 μmol/L of the nonhydrolyzable LPA analog 1-
oleoyl-2-O-methyl-rac-glycerophosphothionate (OMPT) (n = 3). *P< 0.01 by 1-way ANOVA.
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the heart in response to cardiomyopathy, so we measured their levels in
the failing Plpp3Δ hearts. As shown in Fig. 3D, an increase in the ex-
pression of these cardiomyocyte stress-response genes was observed.
Together, these results suggest that LPP3 is essential for cardiac func-
tion. Since the role of LPP3 is dephosphorylation of LPA, we measured
LPA levels in the plasma. The circulating plasma levels of LPA were
increased ≈ 2-fold in the Plpp3Δ mice as compared to Plpp3fl littermates
(Fig. 3E).
3.4. LPP3 negatively regulates LPA signaling responses in cardiomyocytes
Lipid phosphatase activity measured in LPP3 immunoprecipitates
accounted for less than 5% phosphatase activity in Plpp3Δ cardiomyo-
cytes confirming that LPP3 is the predominant isoform in the myo-
cardium (Fig. 4A). Furthermore, direct measurement of lipids in intact
cells to determine LPA phosphatase activity showed that exogenously
applied C17-LPA was degraded 6-fold more slowly by Plpp3Δ than
control cells (Fig. 4A). Treatment with LPA led to a significantly higher
increase in cell surface area in the Plpp3Δ cardiomyocytes. The number
of ANF (Atrial Natriuretic Factor) positive cells, a biomarker of cardi-
ovascular disease, was also higher in Plpp3Δ cardiomyocytes (Fig. 4B).
The lack of LPP3 in cardiomyocytes enhanced LPA-mediated phospho-
ERK activation by increasing and prolonging ERK phosphorylation. In
comparison to Plpp3fl cardiomyocytes, Plpp3Δ cardiomyocytes demon-
strated a robust increase in LPA-induced phospho-ERK activation that
persisted for up to 30 min (P< 0.001; Fig. 4C). Additionally, Plpp3Δ
cardiomyocytes responded to lower levels of LPA, with an ≈ 3-fold
increase in ERK activation at 5 min in response to 1 μM LPA (P<0.001;
Fig. 4C). Expression of murine or human LPP3, but not a catalytically
inactive LPP3 mutant, rescued the phenotype of Plpp3Δ cardiomyocytes
by reducing phosphorylation of ERK in response to LPA (Fig. 4D). Rho
activation in response to LPA was also enhanced in Plpp3Δ cardio-
myocytes (P< 0.001) and was corrected by overexpression of either
murine or human LPP3, but not a catalytically inactive mutant
(Fig. 4E). If LPP3-deficient cells showed enhanced LPA-signaling due to
a reduction in LPA degradation, then the Plpp3Δ cardiomyocytes should
respond normally to a poorly hydrolyzable receptor-active LPA mi-
metic, such as the ester-linked thiophosphate derivative (1-oleoyl-2-O-
methyl-rac-glycerophosphothionate, OMPT). To emphasize the need for
enzymatic catalytic function, we found that OMPT-stimulated ERK ac-
tivation responses of Plpp3fl and Plpp3Δ cardiomyocytes were similar
(Fig. 4F).
3.5. LPP3 is required for cardiomyocyte mitochondrial respiration and
function
Since the mitochondrial damage was observed, as shown in Fig. 2,
we isolated mitochondria from the myocardium of the 8-month-old
Plpp3Δ mice. These were used to determine the impact of LPP3 on mi-
tochondrial bioenergetics. Mitochondria from Plpp3Δ hearts showed a
significant decrease (P< 0.001; Fig. 5A and B) in the basal oxygen
consumption rate, mitochondrial ATP production, maximal respiration
and spare respiratory capacity when compared to the same parameters
found in mitochondria from Plpp3fl hearts. To further clarify the role of
LPP3 in the myocardium, we used neonatal cardiomyocytes to de-
termine the mitochondrial activity and superoxide levels. There also
was a significant reduction in the basal oxygen consumption rate, mi-
tochondrial ATP production, maximal respiration and spare respiratory
capacity of neonatal Plpp3Δ cardiomyocytes (P<0.001; Fig. 5C and D).
We examined glycolysis in these neonatal cardiomyocytes by ECAR,
and the opposite pattern to OCR was observed for glycolysis rates be-
tween Plpp3Δ and Plpp3fl cardiomyocytes (Fig. 5E). The reverse relation
of oxidative phosphorylation and glycolysis rates indicated changes in
the metabolism for energy generation in Plpp3Δ and Plpp3fl cardio-
myocytes and is indicative of an early mitochondrial dysfunction in
Plpp3Δ hearts. Then, we determined the free radical regulation of Plpp3Δ
cardiomyocytes by measuring the superoxide anion using a fluorescent
cholesterol analog, dihydroethidium. Increased basal superoxide pro-
duction was observed in neonatal Plpp3Δ cardiomyocytes. When treated
with LPA, Plpp3Δ cardiomyocytes showed higher superoxide levels as
compared to LPA-treated Plpp3fl cells. LPA-induced superoxide pro-
duction was lowered by the addition of mitoTEMPO, a mitochondrial-
specific superoxide scavenger. A similar reduction of superoxide was
observed by the reintroduction of LPP3 expression (Fig. 5F). These
findings point to the significance of LPP3 expression in mitochondrial
Fig. 4. (continued)
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oxidative phosphorylation as well as in the normal physiology of the
myocardium in adult mice.
4. Discussion
LPP3 is a regulator of cell signaling because of its role in the de-
phosphorylation of LPA, which has been implicated in the many car-
diovascular diseases [10,11,8]. To provide insight into the role of LPP3
in the cardiovascular system, we developed the heart specific Plpp3
knockout mice. The data obtained in Plpp3Δ mice indicate that although
lack of LPP3 in the cardiomyocytes allows for the normal development
of the heart, it is critical for optimal functioning in adult mice. Several
independent genome-wide association studies revealed a link between a
frequently occurring polymorphism in the Plpp3 locus with an increased
risk of coronary artery disease [19–21]. Our previous studies demon-
strated that lack of LPP3 in endothelial and a subset of hematopoietic
cells resulted in embryonic lethality with striking cardiovascular de-
velopment defects [6]. Although the effects of LPP3 have been widely
studied, little is known about LPA-mediated signaling pathways that are
regulated by LPP3 in the myocardium.
In the current study, we have demonstrated that the absence of
LPP3 in cardiomyocytes leads to progressive heart failure and a sig-
nificantly shortened life span in mice (Fig. 3). Cardiac specific deletion
of Plpp3 results in mice which survive and are fertile but more inter-
estingly, their cardiac function and structure are normal at younger age,
suggesting that either LPP3 expressed in the cardiomyocytes does not
play an essential role in early cardiovascular development or the alpha
myosin heavy chain – Cre/loxP system used in the generation of these
mice allows LPP3 expression in the cardiomyocytes during early em-
bryogenesis.
These mice have normal cardiac function and histology up to 3
months of age. Although these mice seem to have no cardiac functional
abnormalities at a young age, it is possible that use of more invasive
measurements along with increased cardiac workload may uncover
underlying conditions. After 7 months of age, the lack of LPP3 in Plpp3Δ
mice resulted in a two-fold increase in the circulating LPA compared to
its Plpp3fl counterparts. Left ventricular (LV) function, as measured by
the percent of fractional shortening (%FS) and ejection fraction (%EF),
was prominently decreased in Plpp3Δ mice. Also, cardiomyocyte dis-
array and sarcomere disruption were evident in the failing hearts that
lacked LPP3. Furthermore, transmission electron micrograph studies
revealed fragmentation and disorientation of myofibrils, distinct dis-
ruption of the intercalated discs, intermyofibrillar edema, rupture of
cristae and double membrane with deposition of amorphous dense
bodies in the failing myocardium of the Plpp3Δ mice.
The use of neonatal cardiomyocytes allowed us to show that LPP3
regulates LPA-mediated phosphorylation of ERK, Rho activation, car-
diomyocyte hypertrophy and genetic markers of cardiac stress such as
atrial natriuretic factor (Nppa) and B-type natriuretic peptide (Nppb).
Although LPP1 and LPP2 have the same catalytic function as that of
LPP3, gene inactivation of Plpp1 or Plpp2 has been reported to produce
no phenotypic alteration in the myocardium [5,22,23]. Furthermore,
direct measurements of intact cell LPA phosphatase activity in our
Plpp3Δ cardiomyocytes demonstrated that LPP3 is the major isoform
that regulates the LPA-mediated signaling in the myocardium. Since
LPP3 also regulates the dephosphorylation of PA, which is known to
induce cardiac hypertrophy [24], further studies are needed to de-
termine the effect of cardiomyocyte specific LPP3 knockout on other
phospholipids in the myocardium.
The fatty acid is considered to be the major metabolic substrate for
the normal adult heart at resting stage. Glucose and lactate account for
about 25–30% of myocardial ATP production. Although glucose is not
the predominant fuel for the adult heart at resting stage as compared to
that of the neonatal cardiomyocytes, the heart switches substrate pre-
ference from fatty acid to glucose at many circumstances during stress
such as ischemia and pathological hypertrophy [25]. Studies have
shown simple glycerophospholipid LPA-mediated ROS production in
cell culture models [26,27], however, its effect on mitochondrial
bioenergetics in cardiomyocytes needs more research. Our real-time
observation studies on mitochondrial oxidative phosphorylation status
revealed mitochondrial dysfunction with increased production of su-
peroxide (a normal byproduct of oxidative phosphorylation that is
formed at increased rates when the electron transport chain is defec-
tive) in the cardiomyocytes that lack LPP3. Oxidative stress was miti-
gated by the re-expression of LPP3. These findings indicate an im-
portant role for LPP3 in the prevention of oxidative stress caused by
mitochondrial dysfunction. Our data add to the weight of the evidence
that LPP3 regulates cardiomyocyte function. Although the lack of LPP3
clearly impairs LPA degradation and inactivation, additional non–LPA-
dependent mechanisms of LPP3 action could also affect cardiomyocyte
function. For example, LPP3 have non-enzymatic functions mediated by
integrin binding or β-catenin signaling [5,28].
Emerging evidence supports a role for lysophospholipid mediators
in the regulation of cardiac development and function [6,7,28]. Our
findings provide functional evidence for a novel role of LPP3 mediated
lipid metabolism in adult myocardium. Longer VERPs observed in
Plpp3Δ mice could mean that the action potentials are longer in these
animals, which could then cause early and delayed afterdepolarizations
leading to arrhythmias [29,30]. Infusion of LPA in rabbits increases
ventricular arrhythmia and the proportion of non-phosphorylated
connexin43, which may inhibit junction transmission [31]. Whether
LPP3 regulates any of these responses is not known. Future studies
should address these intriguing questions.
Fig. 5. Mitochondrial activities in Plpp3Δ mitochondria (A and B) and neonatal cardio-
myocytes. (C and D). Oxygen consumption rate (OCR, pmol/min/µg protein) determined
with XF24 analyzer oxidative phosphorylation activity. Extracellular acidification rate
(ECAR) by XF24 analyzer for glycolysis activity (E). Superoxide radicals produced in the
cardiomyocytes were analyzed using a dihydroethidium fluorescence probe (F). All values
are mean± SD (n = 5). *P< 0.05 as compared to control; #P< 0.05 as compared to LPA
(1 µM) stimulated cells.
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5. Conclusions
The results presented in this study indicate that the loss of LPP3 in
cardiomyocytes impairs the myocardial function. Importantly, we de-
monstrate that LPP3 is a modifier of LPA-mediated signaling in the
myocardium. Taken together, this study is crucial for the understanding
of the importance of LPP3 in the preservation of cardiac structure and
function. In addition, this model also provides an important tool for
furthering our knowledge in the understanding of LPA signaling in
cardiomyocytes pertaining to various heart diseases.
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